Oxurion NV - Company Profile
Powered by 
All the data and insights you need on Oxurion NV in one report.
$295
- Save hours of research time and resources with
our up-to-date Oxurion NV Strategy Report
- Understand Oxurion NV position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Oxurion NV (Oxurion), formerly ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer therapeutics. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion’s product pipeline includes THR-687, a pan-RGD integrin antagonist being developed for the treatment of diabetic retinopathy, and THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME). It has commercialization agreements with companies such as BioInvent International, Quintiles Outcome Sciences, Bicycle Therapeutics, Galapagos, Parexel, INC Research, Patheon, Grifols Inc, and Alcon. It has a presence in Belgium, Ireland and the US. Oxurion is headquartered in Leuven, Flemish Brabant, Belgium.
Headquarters
Belgium
Address
Gaston Geenslaan 1, Leuven (Louvain), 3001
Website
www.oxurion.com
Telephone
32 16 751310
No of Employees
20
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OXUR (EBR)
Revenue (2022)
$284,400
-55.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
40.1%
(2022 vs 2021)
Market Cap*
$970,000
Net Profit Margin (2022)
XYZ
-35.4%
(2022 vs 2021)
* As of and is in US$
Oxurion NV premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Jetrea (Ocriplasmin): | Jetrea |
| Vitreomacular Adhesion (VMA) and Vitreomacular Traction (VMT) | |
| Pipeline: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In November, the company announced its plans to file for bankruptcy. |
| 2021 | Financing Agreements | In April, the company announced to secure EUR30 million investment from Negma Group. |
| 2020 | Contracts/Agreements | In March, the company has entered into global license agreement with Inceptua Group for the commercialization of Jetrea. |
Competitor Comparison
| Key Parameters | Oxurion NV | Amakem NV | Azad Pharma AG | Kubota Vision Inc | Oncotelic Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | Belgium | Belgium | Switzerland | United States of America | United States of America |
| City | Leuven (Louvain) | Diepenbeek | Toffen | Seattle | Agoura Hills |
| State/Province | - | Limbourg | Bern | Washington | California |
| No. of Employees | 20 | - | - | - | 22 |
| Entity Type | Public | Private | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tom Graney | Director; Chief Executive Officer | Executive Board | 2021 | - |
| Kathleen Paisley | Chief Legal Officer; General Counsel | Senior Management | - | - |
| Grace Chang, M.D., Ph.D | Chief Medical Officer | Senior Management | 2020 | - |
| Andy De Deene, M.D. | Chief Development Officer | Senior Management | - | - |
| Patrik De Haes | Chairman | Non Executive Board | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer